

**CV – PETER NAREDI**

**Higher education qualification.** 1982, Läkarexamen (Medical doctor exam), Lunds university.

**Degree of Doctor.** 1992, Subject: Surgery. University of Gothenburg. “Tumour blood flow – methodology and determining factors. A study in rats”. Supervisor: prof LO Hafström.

**Postdoctoral position.** 1993 – 1994; Fellow at the Laboratory of Pharmacology, Cancer Center, University of California, San Diego, USA.

**Docent level.** 1995, Docent in Surgery at University of Gothenburg.

**Present position:** Professor/Överläkare (Professor/Senior consultant) at Department of surgery, Institute Clinical Sciences, Sahlgrenska academy and Sahlgrenska university hospital, University of Gothenburg. 67% research in position. Proprefekt Institute Clinical Sciences and Head Department of surgery. Holds permanent position since October 1, 2012.

**Previous positions and periods of appointment.**

1982-1984 AT tjänstgöring (Internship), Varberg hospital.

1984-1988 Specialistläkarutbildning i kirurgi (Residency Surgery), Halmstad county hospital.

1988-1989 Avdelningsläkare i kirurgi (Ward physician), Halmstad county hospital.

1989-1994 Avdelningsläkare i kirurgi, Sahlgrenska university hospital, Gothenburg.

1994-1997 Vik universitetslektor/överläkare i kirurgi (temporary University lecturer/Senior consultant), Sahlgrenska university hospital, Gothenburg.

1997-2003 Universitetslektor/överläkare i kirurgi, Umeå university hospital.

2003-2012 Professor/överläkare (Professor/Senior consultant), Umeå university hospital.

**Supervision**

*PhD students (disputerade)(supervisor)*

Magnus Rizell, 2003, University of Gothenburg. Mikael Öman, 2004, Umeå university. Oskar Hemmingsson, 2010, Umeå university. Ida Bodén, 2012, Umeå university. Bala Natarajan, 2012, Umeå university.

*PhD students (disputerade)(co-supervisor):*

Per Lindner, 1996, University of Gothenburg. Daniel Öhlund, 2010, Umeå university. Peter Lundgren, 2012, Umeå university. Otto Henriksson, 2012, Umeå university. Hanna Nyström, 2013, Umeå university. Ola Billing, 2014, Umeå university.

*Postdocs*

Gautam Kao, PhD, 2003-05. Rahul Gaur, PhD, 2013-15. Johan Boughardt Fagman, PhD, 2014-16.

**Selected national and international committee/board positions:**

President ECCO (European CanCer Organisation) 2016- ongoing and President-elect 2014-15 and board member 2010-14

Chairman Acta Chirurgica Scandinavica 2012- ongoing

Chairman Swedish surgical association 2008-11

President ESSO (European society of surgical oncology), 2010-12

Chairman Scandinavian surgical society 2009-11

President-elect ESSO (European society of surgical oncology), 2008-10 and Past-president 2012-14

Chairman Educational and training committee ESSO, 2004-06

Chairman Educational committee FECS (Federation of European Cancer Societies), 2005-06

Member of Swedish melanoma study group 1997-ongoing

Chairman Employment and Docent committee (Anställnings- och Docenturnämnd), Medical faculty, Umeå university 2011-12

British Journal of surgery council member 2008-present

American Association of Cancer Research (AACR) task force Surgical oncology 2014-

**Awards**

Honorary member of the European Society for Therapeutic Radiology and Oncology (ESTRO). 2012

Honorary member of the Society of Italian Surgical Oncology (SICO). 2012

Honorary member of the Swedish Surgical Society. 2012

Honorary member of the Hellenic society of Surgical Oncology. 2013

Honary member of BASO – the Association of Cancer Surgery, UK. 2015

**Invited lecturer/chairman at international conferences**

USA, Spain, Poland, England, Italy, Russia, Finland, Denmark, France, Scotland, Netherlands and Japan. 1998 - present

**Selected Research grants (national and international as main applicant):**

1995 - 98 Swedish medical research foundation (MFR)

1995 – 2006, 2008-09, 2012-18 Swedish Cancer foundation

2008-10 Swedish research council (VR) medicine

2004-06 EU grant IP programme (Sokrates): European elective courses in oncology

2006-08 Kempe foundation, Development of surgical simulators, with Stanford university.

2007 Novo Nordic foundation.

2012 IngaBritt and Arne Lundbergs Research foundation.

2012-17 ALF means Västra Götaland Region.

**References (selected out of 136)**

1. Norlin, S., Parekh, V., Naredi, P., Edlund, H. Asn1/TRC40 controls beta cell function and ER homeostasis by ensuring retrograde transport. **Diabetes**. 65 (1):110-119, 2016.
2. Naredi, P., La Quaglia, M. The future of trials in surgical oncology. **Nature Reviews Clinical Oncology** 12:425-31, 2015.
3. Einarsdottir, B., Olofsson Bagge, R., Bhadury, J., Jespersen, H., Mattsson, J., Nilsson, L., Truvé, K., Dávila López, M., Naredi, P., Nilsson, O., Stierner, U., Ny, L., Nilsson, J. Melanoma patient-derived xenografts accurately models the disease and develop fast enough to guide treatment decisions. **Oncotarget** 5(20):9609-18, 2014
4. Eriksson, H., Lyth, J., Månsson-Brahme, E., Frohm-Nilsson, M., Ingvar, C., Lindholm, C., Naredi, P., Stierner, U., Carstensen, J., Hansson, J. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population based study from Sweden. **J Clin Oncol** 32(13):1356-64, 2014.
5. Sullivan, R., Peppercorn, J., Sikora, K., Naredi, P., et al. Delivering affordable cancer care in high income countries. **Lancet Oncol** 12(10):933-80, 2011.
6. Palm, M., Weise, C., Lundin, C., Wingsle, G., Nygren, Y., Björn, E., Naredi, P., Wolf-Watz, M., Wittung-Stafshede, P. Cisplatin binds human copper chaperone Atox1 and promotes unfolding *in vitro*. **Proc Natl Acad Sci USA** 108(17):6951-6, 2011.
7. Hemmingsson, O., Kao, G., Still, M., Naredi, P. ASNA-1 activity modulates sensitivity to cisplatin. **Cancer Res** 70(24):10321-8, 2010.
8. Kao, G., Nordenson, C., Still, M., Rönnlund, A., Tuck, S., Naredi, P. ASNA-1 positively regulates insulin secretion in *C. elegans* and mammalian cells. **Cell** 128:577-87, 2007.
9. Agarwala, S., Glaspy, J., O'Day, S., Mitchell, M., Gutheil, J., Whitman, E., Gonzalez, R., Hersh, E., Feun, L., Belt, R., Meyskens, F., Hellstrand, K., Wood, D., Kirkwood, J.M., Gehlsen, K.R., Naredi, P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. **J Clin Oncol** 20:125-33, 2002.
10. Kurdi-Haidar, B., Aebi, S., Heath, D., Zheng, H., Enns, R.E., Naredi, P., Hom, D.K., Howell, S.B. Isolation of the ATP-binding human homolog of the *arsA* component of the bacterial arsenite transporter. **Genomics** 36:486-91, 1996.
11. Hellstrand, K., Brune, M., Mellqvist, U-H. Naredi, P. Histamine, cimetidin and colorectal cancer. **Nature Med** 2:364-5, 1996.
12. Naredi, P., Heath, D. D., Enns, R. E., Howell, S.B. Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. **J Clin Invest** 95:1193-8, 1995.